Invokana information page | Napp Pharmaceuticals

Your browser is not supported.

To view this content, please use one of the following browsers:

Microsoft Edge
Chrome
Safari

Thank you for visiting our website.

Menarini now distribute Invokana® (canagliflozin) and Vokanamet® (canagliflozin + metformin) in the United Kingdom. This is effective as of 02 January 2023. For adverse event reporting please contact the local Napp or Menarini office as per the product packaging.

GO TO HOME

Reporting adverse events

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.

Adverse events should also be reported to Napp Pharmaceuticals Limited on 01223 424444 or drugsafetyUKandROI@mundipharma.com.

Report An Adverse Event

Reporting adverse events